Levoice-3D Tablet SR is a combination pharmaceutical formulation containing Montelukast 10 mg, Fexofenadine 120 mg, and Acebrophylline 200 mg, designed for the management of respiratory conditions characterized by bronchoconstriction, inflammation, and allergic symptoms. Montelukast, a leukotriene receptor antagonist, effectively reduces airway inflammation and bronchospasm by blocking leukotriene D4 receptors, thereby preventing bronchoconstriction and mucus secretion. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, alleviating allergic manifestations such as rhinorrhea, sneezing, and nasal congestion without causing significant sedation. Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, facilitates airway clearance by relaxing bronchial smooth muscles and reducing mucus viscosity, enhancing respiratory function. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance through once-daily dosing. Levoice-3D Tablet SR is indicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma, and allergic rhinitis, providing comprehensive symptom control by addressing multiple pathophysiological pathways. It should be used under medical supervision, with caution in patients with hepatic or renal impairment. Adverse effects may include headache, gastrointestinal disturbances, and mild sedation. This combination therapy offers an integrated approach to managing complex respiratory disorders, improving quality of life and respiratory function.